Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea
- PMID: 11788208
- DOI: 10.1016/s0735-1097(01)01744-2
Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea
Abstract
Objectives: Since B-type natriuretic peptide (BNP) is secreted by the left ventricle (LV) in response to volume elevated LV pressure, we sought to assess whether a rapid assay for BNP levels could differentiate cardiac from pulmonary causes of dyspnea.
Background: Differentiating congestive heart failure (CHF) from pulmonary causes of dyspnea is very important for patients presenting to the emergency department (ED) with acute dyspnea.
Methods: B-natriuretic peptide levels were obtained in 321 patients presenting to the ED with acute dyspnea. Physicians were blinded to BNP levels and asked to give their probability of the patient having CHF and their final diagnosis. Two independent cardiologists were blinded to BNP levels and asked to review the data and evaluate which patients presented with heart failure. Patients with right heart failure from cor pulmonale were classified as having CHF.
Results: Patients with CHF (n = 134) had BNP levels of 758.5 +/- 798 pg/ml, significantly higher than the group of patients with a final diagnosis of pulmonary disease (n = 85) whose BNP was 61 +/- 10 pg/ml. The area under the receiver operating curve, which plots sensitivity versus specificity for BNP levels in separating cardiac from pulmonary disease, was 0.96 (p < 0.001). A breakdown of patients with pulmonary disease revealed: chronic obstructive pulmonary disease (COPD): 54 +/- 71 pg/ml (n = 42); asthma: 27 +/- 40 pg/ml (n = 11); acute bronchitis: 44 +/- 112 pg/ml (n = 14); pneumonia: 55 +/- 76 pg/ml (n = 8); tuberculosis: 93 +/- 54 pg/ml (n = 2); lung cancer: 120 +/- 120 pg/ml (n = 4); and acute pulmonary embolism: 207 +/- 272 pg/ml (n = 3). In patients with a history of lung disease but whose current complaint of dyspnea was seen as due to CHF, BNP levels were 731 +/- 764 pg/ml (n = 54). The group with a history of CHF but with a current COPD diagnosis had a BNP of 47 +/- 23 pg/ml (n = 11).
Conclusions: Rapid testing of BNP in the ED should help differentiate pulmonary from cardiac etiologies of dyspnea.
Comment in
-
Utility of a BNP as a marker for RV dysfunction in acute pulmonary embolism.J Am Coll Cardiol. 2002 Jun 19;39(12):2080. doi: 10.1016/s0735-1097(02)01915-0. J Am Coll Cardiol. 2002. PMID: 12084612 No abstract available.
Similar articles
-
Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department.Acad Emerg Med. 2003 Mar;10(3):198-204. doi: 10.1111/j.1553-2712.2003.tb01990.x. Acad Emerg Med. 2003. PMID: 12615582
-
B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea.Ann Emerg Med. 2002 Feb;39(2):131-8. doi: 10.1067/mem.2002.121483. Ann Emerg Med. 2002. PMID: 11823766 Clinical Trial.
-
[Levels of serum brain natriuretic peptide in children with congestive heart failure or with severe pneumonia].Zhongguo Dang Dai Er Ke Za Zhi. 2006 Jun;8(3):201-4. Zhongguo Dang Dai Er Ke Za Zhi. 2006. PMID: 16787591 Chinese.
-
Brain natriuretic peptide (BNP) testing in the emergency department.J Emerg Med. 2006 Aug;31(2):201-10. doi: 10.1016/j.jemermed.2005.08.022. J Emerg Med. 2006. PMID: 17044584 Review.
-
Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure.Cleve Clin J Med. 2006 Feb;73(2):149-52, 155-7. doi: 10.3949/ccjm.73.2.149. Cleve Clin J Med. 2006. PMID: 16478039 Review.
Cited by
-
Implementation of the Care Bundle for the Management of Chronic Obstructive Pulmonary Disease with/without Heart Failure.J Clin Med. 2024 Mar 12;13(6):1621. doi: 10.3390/jcm13061621. J Clin Med. 2024. PMID: 38541845 Free PMC article. Review.
-
Rapid N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Kit as a Differentiating Tool for Acute Dyspnea in a Resource-Limited Setting.Cureus. 2023 Nov 5;15(11):e48306. doi: 10.7759/cureus.48306. eCollection 2023 Nov. Cureus. 2023. PMID: 38058332 Free PMC article.
-
Objective Methods of Assessing Fluid Status to Optimize Volume Management in Kidney Disease and Hypertension: The Importance of Ultrasound.J Clin Med. 2023 Oct 5;12(19):6368. doi: 10.3390/jcm12196368. J Clin Med. 2023. PMID: 37835014 Free PMC article. Review.
-
Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future.Int J Mol Sci. 2022 May 19;23(10):5680. doi: 10.3390/ijms23105680. Int J Mol Sci. 2022. PMID: 35628490 Free PMC article. Review.
-
Brain natriuretic peptide measurements using standard biochemical equipment: Comparisons with conventional immunoassays.PLoS One. 2022 May 24;17(5):e0268895. doi: 10.1371/journal.pone.0268895. eCollection 2022. PLoS One. 2022. PMID: 35609039 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
